Advised on directed issue and private placement for Zealand Pharma
We have assisted the joint financial advisors in connection with the directed issue and private placement of 3,761,470 new ordinary shares in Zealand Pharma A/S, yielding gross proceeds to the company of approx. DKK 1.45 billion.
The case
On 8 January 2024, Zealand Pharma A/S ("Zealand") announced a directed issue and private placement of approximately 3.7 million new shares, at a price of DKK 386.45 per share representing the volume-weighted average price (VWAP) on 8 January 2024 for Zealand's shares quoted on Nasdaq Copenhagen.
Zealand intends to use the net proceeds from the placement to further strengthen Zealand’s investment in its differentiated assets targeting obesity.
Kromann Reumert has assisted Carnegie Investment Bank, filial af Carnegie Investment Bank AB (publ), Sweden and Jefferies GmbH, who acted as joint financial advisors in connection with the directed issue and private placement.
About Zealand
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S.
Contact
